Premium
[P1–587]: CARDIOMETABOLIC DISORDERS ACCELERATE COGNITIVE DECLINE AND TOTAL BRAIN VOLUME LOSS: A POPULATION‐BASED LONGITUDINAL STUDY
Author(s) -
Xu Weili,
Marseglia Anna,
Kalpouzos Gregoria,
Bäckman Lars,
Fratiglioni Laura
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.603
Subject(s) - cognitive decline , medicine , dementia , confounding , prediabetes , population , diabetes mellitus , brain size , gerontology , magnetic resonance imaging , type 2 diabetes , disease , endocrinology , environmental health , radiology
of benzodiazepineswas associatedwith an increased risk of dementia (OR1⁄41.36, 95%CI 1.09-1.70), as was former (OR1⁄41.63, 95%CI 1.51-1.76) but not current use (OR1⁄41.64, 95%CI 0.83-3.27). Studies with no lag time had an increased risk estimate (OR1⁄41.53, 95%CI 1.14-2.04) compared to thosewhich introduced a lag time to eliminate protopathic bias (OR1⁄41.16, 95%CI 1.03-1.31), but importantly the latter resultwas still statistically significant. The association persisted in studies with a 5-year lag time. Conclusions:Benzodiazepine use increases the risk of dementia by about 16%, after corrections to eliminate protopathic bias. Given the high prevalence of benzodiazepine use, this increase in risk would translate into a large number of real cases and hence benzodiazepine prescribing practices should be reviewed.